Table 2 Summary of post-vaccine sera evaluated for neutralization potency against the indicated SARS-CoV-2 variants of concern (VOC).

From: Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

  Neutralization assay (IC50 fold-reduction vs. WT)
Vaccine Company Spike construct B.1.1.7 (Alpha) P.1 (Gamma) B.1.351 (Beta) Number of samples tested (n) Reference (PMID)
Ad26.COV2.S Johnson&Johnson 2P & ΔFurin ≤2× (n.s.) NA ≤5× 8 33909009a
BNT162b2 Pfizer/BioNTech 2P NA ≤6.5× 10 33684923
BNT162b2 Pfizer/BioNTech 2P 2x (n.s.) 6.7× 35x 30 33743213
BNT162b2 Pfizer/BioNTech 2P 3.3x NA NA 25 33743891
BNT162b2 Pfizer/BioNTech 2P NA NA 7.9 25 33730597
mRNA-1273 Moderna 2P 1.8× NA ≤8.6× 12 33684923
mRNA-1273 Moderna 2P (n.s.) 4.5× 28x 35 33684923
BNT162b2 or mRNA-1273 Pfizer/BioNTech or Moderna 2P NA ≤3× NA 15b 33567448
NVX-CoV2373 Novavax 3Q – 2P NA NA 28 33705729
AZD1222 AstraZeneca Native NA NA 13 33725432
AZD1222 AstraZeneca Native 8.9x NA NA 49 33798499
AZD1222 AstraZeneca Native 2.1–2.5x NA NA 25 33743891
AZD1222 AstraZeneca Native NA NA 9x 25 33730597
CoronaVac Sinovac Native NA NA NA N.D. N.D.
BBIBP-CorV Sinopharm Native NA NA 1.6× (n.s.) 12 33870240
Sputnik V Gamaleya Native (n.s.) 2.8x (E484K) 6.1x 12 33821288c
  1. aNon-human Primate data.
  2. bFour are post-Pfizer/BioNTech and 11 are post-Moderna vaccine samples.
  3. cCurrent study.
  4. Table format adapted and updated from Abdool Karim and de Olivera60. 2P 2 proline substitutions in the S2 central helix (K986P/V987P), ΔFurin deletion of furin cleavage site, 3Q–2P RRAR to QQAQ to render furin cleavage site protease resistant combined with the aforementioned two proline substitutions.